Microglia In Huntington'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Huntington's disease (HD) is characterized by selective neurodegeneration of striatal medium spiny neurons and cortical pyramidal neurons, driven by mutant huntingtin (mHTT) expansion. Microglia, the brain's innate immune cells, play a complex role in HD pathogenesis, contributing to neuroinflammation while also attempting to clear pathological protein aggregates and cellular debris.
- IBA1 (AIF1) - ionized calcium-binding adapter molecule 1
- CD68 - lysosomal marker (activated microglia)
- CD11b (ITGAM) - complement receptor 3
- TREM2 - triggering receptor expressed on myeloid cells 2
- TYROBP (DAP12) - adaptor protein for TREM2
- CX3CR1 - fractalkine receptor
- P2RY12 - purinergic receptor
- CD68 upregulation: Chronic activation
- TREM2 expression: In HD microglia
- HLA-DR: MHC class II (activated state)
- LPL (Lipoprotein Lipase): Lipid metabolism in disease
¶ Anatomy and Distribution
- Striatum: Highest microglial density, severe pathology
- Cortex: Layer-specific activation
- Hippocampus: Moderate involvement
- White matter: Subcortical regions
- Early activation: Pre-symptomatic stages
- Progressive increase: With disease progression
- Spatial correlation: With neurodegeneration
- Morphological changes: Amoeboid morphology
- Increased density: 2-3 fold in striatum
- Cluster formation: Around degenerating neurons
- Chronic activation: Sustained pro-inflammatory state
- mHTT in microglia: Cell-autonomous dysfunction
- Impaired phagocytosis: Reduced clearance
- Cytokine dysregulation: Altered secretion
- NLRP3 inflammasome: Enhanced activation
- Cell-autonomous pathology: mHTT in microglia
- Transcriptional dysregulation: Altered gene expression
- Metabolic impairment: Mitochondrial dysfunction
- Protein aggregation: mHTT inclusions
- Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6
- Chemokines: CCL2, CXCL10
- Nitric oxide: ROS production
- Prostaglandins: Cyclooxygenase products
- CX3CL1/CX3CR1: Fractalkine signaling
- CD47/SIRPα: Phagocytic checkpoint
- Complement system: Synaptic pruning
- TREM2/DAP12: Activation signaling
- Energy impairment: Glycolysis defects
- Mitochondrial dysfunction: Complex I-V deficits
- Oxidative stress: ROS accumulation
- Correlation with severity: Microglial activation and clinical scores
- Early marker: Pre-symptomatic activation
- Therapeutic target: Disease modification
- Motor dysfunction: Contributes to chorea
- Cognitive decline: Neuroinflammation role
- Behavioral changes: Cytokine effects on mood
- Minocycline: Inhibits microglial activation
- Coenzyme Q10: Mitochondrial support
- CX3CR1 antagonists: Reduce inflammation
- TREM2 modulation: Protective approaches
- Cytokine inhibitors: TNF-α blockade
- Phagocytosis enhancement: Improve clearance
- HTT lowering: Reduces microglial pathology
- Antisense oligonucleotides: mHTT reduction
- CRISPR approaches: Future therapies
The study of Microglia In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Crotti A, et al. (2014). "Mutant huntingtin promotes neuron-autonomous microglial activation." Nat Neurosci. 17(4):513-521.
- Palpagama TH, et al. (2019). "Microglia in Huntington's disease: from synapse to behavior." Front Cell Neurosci. 13:540.
- Bhattacharyya A, et al. (2020). "The role of microglia in Huntington's disease." Neurobiol Dis. 148:105212.
- Yang X, et al. (2015). "Microglial activation in the brain in Huntington's disease." J Neurochem. 133(5):608-619.
- Politis M, et al. (2011). "Microglial activation in regions related to cognitive function in Huntington's disease." Neurobiol Dis. 41(2):334-344.